Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma.
Souichi YanamotoMasahiro UmedaMitomu KioiTadaaki KiritaTetsuro YamashitaHiroyoshi HiratsukaSatoshi YokooHideki TanzawaNarikazu UzawaTakahiko ShibaharaYoshihide OtaHiroshi KuritaMasaya OkuraHiroyuki HamakawaJingo KusukawaIwai TohnaiPublished in: Cancer chemotherapy and pharmacology (2018)
The results of our multicenter retrospective study, which was the largest of its kind to date, suggest that first-line cetuximab plus platinum-based chemotherapy is suitable and well-tolerated for the systemic therapy of recurrent or metastatic OSCC.